Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 5/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710535 | 0.84 | AHR (0.53) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL6090116 | 0.82 | NPC1 (0.50) | AHRPDE7ACA12CA1CA2 | |
| SCHEMBL22904158 | 0.77 | TDP2 (0.64) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL13312397 | 0.77 | GSK3B (0.41) | AHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL261018 | 0.76 | AHR (0.61) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL1654363 | 0.76 | AHR (0.61) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL19753764 | 0.76 | TDP2 (0.62) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL433799 | 0.76 | AHR (0.61) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL1162926 | 0.76 | AHR (1.00) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL4411843 | 0.76 | AHR (0.61) | AHRPDK2TDP2CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025064802-A1 | INHIBITING HUMAN INTEGRIN α5β1 | MORPHIC THERAPEUTIC, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4433477-A1 | PAD4 INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118679162-A | PAD4 inhibitors and uses thereof | 锐格药业公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024191714-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC | 2024-09-19 | — | — | US | disclosed |
| CN-113004336-B | Transition metal complexes, polymers, mixtures, compositions and organic electronic devices | 广州华睿光电材料有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | FORMAN SCOTT LOUIS (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1313719-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014275-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | PDE3A, PDE3B, PDE5A | AHR 4129/4885PDK2 2179/4885TDP2 926/4885 |
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | PADI4, PADI6, PADI2 | AHR 4145/4885PDK2 467/4885TDP2 34/4885 |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | GRIN2A, GRIN1, GRIN2B | AHR 1065/4885PDK2 1930/4885TDP2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.